Nektar(US:NKTR) Businesswire·2026-03-17 18:37Core Viewpoint - A securities fraud class action lawsuit has been filed against Nektar Therapeutics (NKTR) on behalf of investors who acquired its securities between February 26, 2025, and December 15, 2025, due to alleged misleading statements and failure to disclose material adverse facts about the company's business and operations [1][3]. Summary by Sections Company Overview - Nektar Therapeutics is a biopharmaceutical company involved in developing treatments, including a drug for alopecia areata named rezpegaldesleukin [2]. Lawsuit Details - The lawsuit claims that during the class period, Nektar made materially false and misleading statements regarding the integrity and results of the Phase 2b REZOLVE-AA trial for rezpegaldesleukin [3]. - Specifically, it is alleged that the company failed to disclose that enrollment in the trial did not adhere to applicable protocols, which likely impacted the trial's results negatively [3]. Stock Impact - Following the announcement of the trial results on December 16, 2025, Nektar's stock price dropped by $4.14, or 7.8%, closing at $49.16 per share, resulting in financial harm to investors [2][3]. Investor Actions - Investors who purchased Nektar securities during the class period have until May 5, 2026, to file a lead plaintiff motion in the class action lawsuit [1][4].